|
1
|
Bunn PA Jr and Kelly K: New
chemotherapeutic agents prolong survival and improve quality of
life in non-small cell lung cancer: a review of the literature and
future directions. Clin Cancer Res. 4:1087–1100. 1998.PubMed/NCBI
|
|
2
|
Giaccone G, Splinter TA, Debruyne C, et
al: Randomized study of paclitaxel-cisplatin versus
cisplatin-teniposide in patients with advanced non-small-cell lung
cancer. The European Organization for Research and Treatment of
Cancer Lung Cancer Cooperative Group. J Clin Oncol. 16:2133–2141.
1998.PubMed/NCBI
|
|
3
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robey RW, To KK, Polgar O, et al: ABCG2: a
perspective. Adv Drug Deliv Rev. 61:3–13. 2009. View Article : Google Scholar
|
|
5
|
Nakamura Y, Oka M, Soda H, et al:
Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor
tyrosine kinase inhibitor, reverses breast cancer resistance
protein/ABCG2-mediated drug resistance. Cancer Res. 65:1541–1546.
2005.
|
|
6
|
Yoh K, Ishii G, Yokose T, et al: Breast
cancer resistance protein impacts clinical outcome in
platinum-based chemotherapy for advanced non-small cell lung
cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sereti KI, Oikonomopoulos A, Unno K, Cao
X, Qiu Y and Liao R: ATP-binding cassette G-subfamily transporter 2
regulates cell cycle progression and asymmetric division in mouse
cardiac side population progenitor cells. Circ Res. 112:27–34.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lathia JD, Hitomi M, Gallagher J, et al:
Distribution of CD133 reveals glioma stem cells self-renew through
symmetric and asymmetric cell divisions. Cell Death Dis.
2:e2002011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gonzalez C: Spindle orientation,
asymmetric division and tumour suppression in Drosophila
stem cells. Nat Rev Genet. 8:462–472. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Z, Liu F, Ren Q, et al: Suppression
of ABCG2 inhibits cancer cell proliferation. Int J Cancer.
126:841–851. 2010.PubMed/NCBI
|
|
11
|
To KK, Robey RW, Knutsen T, Zhan Z, Ried T
and Bates SE: Escape from hsa-miR-519c enables drug-resistant cells
to maintain high expression of ABCG2. Mol Cancer Ther. 8:2959–2968.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Litman T, Brangi M, Hudson E, et al: The
multidrug-resistant phenotype associated with overexpression of the
new ABC half-transporter, MXR (ABCG2). J Cell Sci. 113:2011–2021.
2000.PubMed/NCBI
|
|
13
|
Lanzkron SM, Collector MI and Sharkis SJ:
Hematopoietic stem cell tracking in vivo: a comparison of
short-term and long-term repopulating cells. Blood. 93:1916–1921.
1999.PubMed/NCBI
|
|
14
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueda T, Brenner S, Malech HL, et al:
Cloning and functional analysis of the rhesus macaque ABCG2 gene.
Forced expression confers an SP phenotype among hematopoietic stem
cell progeny in vivo. J Biol Chem. 280:991–998. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosell R, Lord RV, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ikuta K, Takemura K, Sasaki K, et al:
Expression of multidrug resistance proteins and accumulation of
cisplatin in human non-small cell lung cancer cells. Biol Pharm
Bull. 28:707–712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu J, Peng H and Zhang JT: Human multidrug
transporter ABCG2, a target for sensitizing drug resistance in
cancer chemotherapy. Curr Med Chem. 14:689–701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doyle LA, Yang W, Abruzzo LV, et al: A
multidrug resistance transporter from human MCF-7 breast cancer
cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ota S, Ishii G, Goto K, et al:
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen
predicts survival in advanced non-small-cell lung cancer treated
with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009.
View Article : Google Scholar
|
|
21
|
Morrison SJ and Kimble J: Asymmetric and
symmetric stem-cell divisions in development and cancer. Nature.
441:1068–1074. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Knoblich JA: Mechanisms of asymmetric stem
cell division. Cell. 132:583–597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shahriyari L and Komarova NL: Symmetric
vs. asymmetric stem cell divisions: an adaptation against cancer?
PLoS One. 8:e761952013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang R, Zhang Z, Zhang C, et al: Stroke
transiently increases subventricular zone cell division from
asymmetric to symmetric and increases neuronal differentiation in
the adult rat. J Neurosci. 24:5810–5815. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barr MP, Gray SG, Hoffmann AC, et al:
Generation and characterisation of cisplatin-resistant non-small
cell lung cancer cell lines displaying a stem-like signature. PLoS
One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Susanto J, Lin YH, Chen YN, et al:
Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of
embryonic stem cells. PLoS One. 3:e40232008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cicalese A, Bonizzi G, Pasi CE, et al: The
tumor suppressor p53 regulates polarity of self-renewing
divisions in mammary stem cells. Cell. 138:1083–1095. 2009.
|
|
28
|
Kim JJ and Tannock IF: Repopulation of
cancer cells during therapy: an important cause of treatment
failure. Nature Rev Cancer. 5:516–525. 2005. View Article : Google Scholar : PubMed/NCBI
|
